New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

//New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors

Not yet recruiting. Study Start Date: July 2016

Contact: Rebecca Wong, M.D. 416-946-2126
rebecca.wong@rmp.uhn.on.ca

4 Locations:

Juravinski Cancer Centre, Hamilton, Ontario, Canada
Contact: Rosalyn Juergens, M.D.

London Health Sciences Centre, London, Ontario, Canada
Contact: David Laidley, M.D.

Princess Margaret Cancer Centre, Toronto, Ontario, Canada
Contact: Rebecca Wong, M.D.

Sunnybrook Research Institute, Toronto, Ontario, Canada
Contact: Sten Myrehaug, M.D.

For more information on the trial:
https://clinicaltrials.gov/ct2/show/NCT02743741

 

By | 2018-05-07T18:28:13+00:00 June 5th, 2016|Clinical Trial|Comments Off on New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

About the Author: